Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie.

Looking at options history for $AbbVie (ABBV.US)$ we detected 15 trades.

If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 46% with bearish.

From the overall spotted trades, 3 are puts, for a total amount of $162,900 and 12, calls, for a total amount of $749,820.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $185.0 for AbbVie over the last 3 months.

Volume & Open Interest Development

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $75.0 to $185.0, over the past month.

AbbVie 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.

Present Market Standing of AbbVie

• With a volume of 2,217,156, the price of ABBV is up 1.13% at $169.78.

• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.

• Next earnings are expected to be released in 3 days.

What Analysts Are Saying About AbbVie

1 market experts have recently issued ratings for this stock, with a consensus target price of $195.0.

• Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for AbbVie, targeting a price of $195.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from Benzinga Pro.